Visceral
pain is the most
frequent form of clinically relevant pain for those patients seek medical
attention. There are several causes of visceral pain. Nociceptive pain causes
direct injury of an internal organs, that leads to cardiac ischemic, and peptic
ulcer. Medications for visceral pain treatment includes analgesics such as
nonsteroidal anti-inflammatory drugs, paracetamol and serotonergic compounds.
Opioids are
also used for the treatment of a range of acute to chronic visceral pains.
Sacral nerve stimulation for interstitial cystitis and psychological management
are some non-pharmacological treatment available for the management of visceral
pain.
The drug
candidates in visceral pain therapeutics pipeline include, but not limited to,
NEO5937, ANAVEX 1066 and APD371. Neomed Management AS, Arena Pharmaceuticals
Inc. and Anavex Life Sciences Corp. are some of the major companies having
drugs in the visceral pain therapeutic pipeline.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment